Activity Overview
This online, on-demand virtual symposium brings together renowned experts in small cell lung cancer (SCLC). In this educational program, these experts discuss the implications of recent clinical trial data describing new and emerging therapies in each key treatment setting. Panel discussions focus on identifying optimal approaches at key decision points, including first-line treatment selection, supportive care approaches, maintenance therapy, and management of relapsed disease.
This educational activity is an archive of the live symposium held on February 20, 2026.
Target Audience
This educational activity is directed toward medical and thoracic oncologists, pulmonologists, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the management of SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop personalized treatment plans for limited- and extensive-stage SCLC based on evolving clinical trial evidence and guideline recommendations
- Incorporate proactive strategies to monitor and mitigate treatment-related toxicities in patients with SCLC
- Evaluate emerging therapeutic strategies and consider potential implications in the context of evolving paradigms across the SCLC treatment continuum
Charles M. Rudin, MD, PhD
Deputy
Director
Memorial
Sloan Kettering Cancer Center
New
York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Merck, Roche; Grant/Research Funding: Amgen, Daiichi Sankyo, Merck; Royalty or Patent Benefits: Licensing and royalty payments related to DLL3 therapeutics
Alex A. Adjei, MD, PhD
Chief, Cancer
Institute
Cleveland
Clinic
Cleveland, OH
Disclosures: Alex A. Adjei, MD, PhD, has no relevant financial relationships with ineligible companies.
Millie Das, MD
Clinical
Professor, Medicine – Oncology
Stanford
Cancer Institute
Chief,
Oncology
VA Palo Alto
Health Care System
Palo Alto, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Janssen, Jazz, Lilly, Merus, Natera, Novartis, OncoHost, RayzeBio, Regeneron, Summitt; Grant/Research Funding: CellSight, Genentech, Merck, Varian; Executive Role: President of ANCO (Association of Northern CA Oncologists)
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc; Jazz Pharmaceuticals, Inc; Merck Sharp & Dohme, LLC.
PER® is proud to partner with the LUNGevity Foundation.
